Literature DB >> 20065047

Amphotericin B therapy in children with visceral leishmaniasis: daily vs. alternate day, a randomized trial.

Utpal Kant Singh1, Rajniti Prasad, Bir Prakash Jaiswal, Prabhat Kumar Singh, C P Thakur.   

Abstract

A randomized study was carried out to compare the efficacy and adverse reactions of daily vs. alternate day regimens of amphotericin B in children with visceral leishmaniasis (VL). Six hundred and five children of VL below 14 years of age were randomized into two groups; Group A (302), who received amphotericin B at a dose of 1 mg kg(-1) day(-1) for 15 days and Group B (303); same doses but on alternate days. All patients in both groups were cured, who had completed course of amphotericin B therapy. None had relapsed at 1 and 6 months of follow-up. Adverse reactions in both groups were non-significant. The duration of stay and cost of therapy was significantly lower in Group A children who left the hospital against medical advice, which was also significantly more in Group B. Thus, daily regimen of amphotericin B is equally effective, well tolerated, not more toxic and cost-effective than alternate day regimen, which is currently practiced.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20065047     DOI: 10.1093/tropej/fmp132

Source DB:  PubMed          Journal:  J Trop Pediatr        ISSN: 0142-6338            Impact factor:   1.165


  5 in total

1.  The economic value of a visceral leishmaniasis vaccine in Bihar state, India.

Authors:  Bruce Y Lee; Kristina M Bacon; Mirat Shah; Sara Beth Kitchen; Diana L Connor; Rachel B Slayton
Journal:  Am J Trop Med Hyg       Date:  2012-03       Impact factor: 2.345

2.  Peroral amphotericin B polymer nanoparticles lead to comparable or superior in vivo antifungal activity to that of intravenous Ambisome® or Fungizone™.

Authors:  Jagdishbhai L Italia; Andrew Sharp; Katharine C Carter; Peter Warn; M N V Ravi Kumar
Journal:  PLoS One       Date:  2011-10-06       Impact factor: 3.240

Review 3.  Therapeutic options for visceral leishmaniasis.

Authors:  Begoña Monge-Maillo; Rogelio López-Vélez
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

4.  Species-directed therapy for leishmaniasis in returning travellers: a comprehensive guide.

Authors:  Caspar J Hodiamont; Piet A Kager; Aldert Bart; Henry J C de Vries; Pieter P A M van Thiel; Tjalling Leenstra; Peter J de Vries; Michèle van Vugt; Martin P Grobusch; Tom van Gool
Journal:  PLoS Negl Trop Dis       Date:  2014-05-01

Review 5.  Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective.

Authors:  Om Prakash Singh; Bhawana Singh; Jaya Chakravarty; Shyam Sundar
Journal:  Infect Dis Poverty       Date:  2016-03-08       Impact factor: 4.520

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.